Merck: agreement extended with Daiichi Sankyo
(CercleFinance.com) - Merck announces that it has extended its worldwide agreement with Daiichi Sankyo to include MK-6070.
Developed by Merck, this drug will be marketed jointly by both partners worldwide, except in Japan, where Merck will retain exclusive rights, manufacturing and supply.
MK-6070, which is intended for the treatment of small-cell lung cancer (SCLC) and neuroendocrine tumors, is currently in clinical trial 1/2.
The companies will evaluate its use in combination with ifinatamab deruxtecan (I-DXd) for the treatment of SCLC.
Both companies expressed their enthusiasm for the collaboration, underlining the urgent need for new therapies for SCLC.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Developed by Merck, this drug will be marketed jointly by both partners worldwide, except in Japan, where Merck will retain exclusive rights, manufacturing and supply.
MK-6070, which is intended for the treatment of small-cell lung cancer (SCLC) and neuroendocrine tumors, is currently in clinical trial 1/2.
The companies will evaluate its use in combination with ifinatamab deruxtecan (I-DXd) for the treatment of SCLC.
Both companies expressed their enthusiasm for the collaboration, underlining the urgent need for new therapies for SCLC.
Copyright (c) 2024 CercleFinance.com. All rights reserved.